ArticleCureus2025
Work Reintegration After Chemotherapy in Patients With Early-Stage Breast Cancer: The RESTART Cross-Sectional Survey.
Article in Cureus, 2025. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Not yet cited in PubMed.
What it found
Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.
The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.
The trial behind it
Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.
Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.
Who cites it
0 citing papers in PubMed.
No citing paper in PubMed yet.
Corrections and comments
PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.
Authors and funding
10 authors.
Funding
No grant is acknowledged in the PubMed record.
Abstract
backgroundReturn to work (RTW) is a key milestone for breast cancer survivors, reflecting financial stability, personal recovery, and social reintegration. However, this transition is often hindered by persistent physical, cognitive, and emotional sequelae of treatment. In this single-center exploratory study within the RESTART project, we aimed to evaluate return-to-work outcomes and identify clinical, psychosocial, and occupational factors associated with sick leave and prolonged work absence in women treated with chemotherapy for early-stage breast cancer.
methodsWe conducted a cross-sectional study in Portugal that included professionally active women (≤60 years) at least 12 months after completing chemotherapy. Data were collected from medical records and patient questionnaires addressing sociodemographic, clinical, and employment-related factors. Quality of life was assessed using the EORTC QLQ-BR23. Multivariable logistic regression was used to identify factors associated with sick leave and prolonged leave (>12 months).
resultsSeventy-one women were included (median age 52 years, interquartile range (IQR) 49-57). Most participants (59, 83.1%) took sick leave, usually starting at diagnosis, and 42 (71.2%) remained on leave after chemotherapy. At evaluation, 48 (81.4%) had returned to work, with a median time of 18 months from diagnosis (IQR 11-30) and 13 months from the end of chemotherapy (IQR 7-27). However, 7 (14.6%) transitioned to part-time work, 13 (27.1%) changed roles, and 11 (22.9%) reported income loss. The most common reasons for continued leave were fatigue (33, 82.5%), cognitive impairment (26, 72.2%), mood changes (20, 55.6%), and insufficient workplace adaptation (17, 53.1%). Physical exercise (34, 64.2%), psychological support (25, 47.2%), and physical therapy (25, 47.2%) were frequently reported as facilitators of return. In multivariable analysis, lower educational level (odds ratio (OR) 4.67, 95% confidence interval (CI) 1.07-20.5,
conclusionsRTW after breast cancer is influenced by medical, occupational, and psychosocial factors. In this exploratory single-center sample, Portuguese survivors experienced substantial work disruption, underscoring the need for integrated survivorship care with vocational support. Interventions should focus on symptom management, employer engagement, and structured work capacity assessment. Public health strategies should acknowledge work reintegration as a core component of post-cancer recovery.
Indexed as
Identifiers
What OpenQuestion holds
Registered trials
Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.